COVID-19 Pfizer Information
Follow Us on Twitter
ADD TO CALENDAR: Current Complexities, New Approaches in the Treatment of Multiple Myeloma.
ADD TO CALENDAR: Navigating the Challenge of Invasive Mould Disease (IMD) Diagnosis and Management: Real-World Case Studies.
Cresemba SmPC Link for capsules - German
Cresemba SmPC Link for IV - German
Cresemba SmPC Link - English
Cresemba Virtual Experience
Cresemba Dosing Guide
Cresemba Key Messaging Leave Piece
Daurismo SmPC Link
Therapy Management Guide
Mylotarg SmPC Link
Salvage Leave Piece - Video Animation
MRD publication summary
HSCT Survival Leaflet
Blast Count Leaflet
Besponsa SmPC Link
Product Overview
BYOND Leaflet
ELN Guidelines for CML
Bosulif SmPC Link
Abstract Plain Language Summaries
This is Living with Cancer
What to Expect With Your Cancer Care During COVID-19 – Spanish Version
What to Expect With Your Cancer Care During COVID-19
Pfizer Oncology Patient Centricity Ecosystem: From Launch to Impact
Connect with Talent Acquisition
Investigator Information and How to Contact Us
Global Medical Grants Oncology Brochure
Reimagining Diversity in Multiple Myeloma Clinical Trials
MagnetisMM-9 Clinical Trial
MagnetisMM-5 Clinical Trial
MagnetisMM-4 Clinical Trial
African American Men’s Health Checklist
African American Men's Health: 3 Options to Learn about Staying Healthy
Current Complexities, New Approaches in the Treatment of Multiple Myeloma
Navigating the Challenge of Invasive Mould Disease (IMD) Diagnosis and Management: Real-World Case Studies
Pfizer Sponsored Scientific Presentations
Pfizer Medical Information
Discover the Oncology Development Program and Clinical Trials
Current Complexities, New Approaches in the Treatment of Multiple Myeloma - Quick Access
advancinghemonccare.com
Hematologic Malignancies
COVID-19 Pfizer Information
Blood Cancer Community Video
Pfizer Oncology Collaborating to Improve Patient Centricity in Clinical Trials
Perspectives by Colleagues Video
Chapter 3: BsAbs as a potential therapeutic approach in MM
Chapter 2: BCMA is a therapeutic target in MM
Chapter 1: Immunosuppression in MM
CRESEMBA MOA Video
CRESEMBA Expert Video – How does presentation of ibrutinib-associated IMD differ, and what should clinicians look out for?
CRESEMBA Expert Video – What is the relationship between ibrutinib and IMI risk?
CRESEMBA Expert Video - How can clinicians suspect and diagnose IMD in emerging at risk patient populations?
CRESEMBA Expert Video – Isavuconazole in patients with renal impairment
CRESEMBA Expert Video – Drug-drug interactions with isavuconazole and voriconazole
Thanks for finding us at EHA 2022
Who We Are and What We Do
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Pfizer has a long and proud heritage of addressing evolving hematologic malignancies and infectious disease challenges that continue to improve the lives of patients around the globe.
Thanks for finding us at EHA 2022
Who We Are and What We Do
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Pfizer has a long and proud heritage of addressing evolving hematologic malignancies and infectious disease challenges that continue to improve the lives of patients around the globe.
Opportunities To Connect
Upcoming Opportunities
to Connect
Upcoming Opportunities to Connect
Product Symposium
A team member will respond to your inquiry.
Product Symposium
Learn About Our Oncology Approved Medicines
Learn About Our Oncology Approved Medicines
Learn About Our Oncology Approved Medicines
PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.
